Diagnostic Discordance and Error in Breast Pathology: Causes, Classifications, and Medicolegal Implications.

Diagnostic pathology is inherently interpretative and subject to interobserver variability. Although diagnostic concordance is a critical quality metric, distinguishing between acceptable variation, diagnostic error, and professional negligence is essential for both clinical care and medicolegal clarity. This review highlights the difference between interobserver variability (diagnostic disagreement/discordance) that remains within acceptable professional limits, diagnostic error (a deviation from expected standards due to cognitive, technical, or systemic factors), and negligence (a repeated, reckless, or unjustified deviation from established standards). Errors in pathology often reflect systemic vulnerabilities, such as workflow inefficiencies, inadequate quality control, or limited biopsy sampling, rather than individual performance alone. They may occur at any stage of the diagnostic pathway (preanalytical, analytical, or postanalytical) and arise from specimen misidentification, contamination or loss, inadequate sampling, or incomplete documentation. Pathologist-related errors encompass failure to recognize significant pathology, misinterpretation, omission of appropriate ancillary studies, insufficient workup of complex cases, including failure to seek a second opinion, or substandard reporting. Medicolegal implications are heightened when such errors result in delayed diagnosis or major misclassification, leading to patient harm. In breast pathology, interobserver variation in the classification of borderline lesions (eg, grading of phyllodes tumors) and in the interpretation of overlapping entities (eg, atypical apocrine lesions) is well recognized. Although such differences may influence management, they should be regarded as acceptable professional variability, rather than error or negligence. To minimize diagnostic risk and uphold standards, structured reporting, vigilance in complex cases, participation in quality assurance, explicit documentation of uncertainty, active multidisciplinary team engagement, and laboratory accreditation are strongly recommended. Supporting pathologists as diagnosticians and patient safety advocates, within a culture of openness, shared learning, and institutional support, remains central to diagnostic accuracy, transparency, and medicolegal defensibility.